Transforming Colorectal Cancer Management with Tumor-Informed ctDNA Testing

Abstract

Get full access to this article

View all access options for this article.

References

Reinert

, et al., Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol . 2019 Aug 1; 5(8):1124-1131. doi: 10.1001/jamaoncol.2019.0528. Erratum in: JAMA Oncol. 2019 Aug 1;5(8):1232.

Nakamura

, Watanabe

, Akazawa

et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med , 30, 3272–3283 (2024).

Shaw

et al., Circulating tumor DNA for Detection of Molecular Residual Disease (MRD) in Patients with Stage II/III Colorectal Cancer (CRC): Final Analysis of the BESPOKE CRC Sub cohort, as presented at presented at the 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).